Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Dana-Farber Cancer Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02279394CT.gov E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | — | Completed | — | — | — |
NCT01441973CT.gov Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Smoldering Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Elotuzumab (this asset) | Dana-Farber Cancer Institute | P2 | B · 58 |
| Nivestim | Regeneron Pharmaceuticals | P3 | BB |
| Dexasone | Regeneron Pharmaceuticals | P3 | BB |
| Linvoseltamab | Regeneron Pharmaceuticals | P3 | BB |
| Lenalidomide | Irene Ghobrial, MD | P3 | BB |
| Daratumumab | Regeneron Pharmaceuticals | P3 | BB |
| Cyclophosphamide | Dana-Farber Cancer Institute | P2 | B |
| Melphalan | PETHEMA Foundation | P3 | B |
| Leflunomide | City of Hope Medical Center | P2 | B |
+39 more in the Smoldering Plasma Cell Myeloma cohort
Other indications for Elotuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P3 | BB · 64 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2 | B · 56 |
| Plasma Cell Leukemia | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Elotuzumab in Smoldering Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/elotuzumab-smoldering-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →